Residual Leukemic Cell Counts in the Bone Marrow at the End Point of Intensive Induction Therapy May be a Prognostic Factor for Acute Myeloblastic Leukemia in Adults-Reference-Cited by-同舟云学术

Residual Leukemic Cell Counts in the Bone Marrow at the End Point of Intensive Induction Therapy May be a Prognostic Factor for Acute Myeloblastic Leukemia in Adults

Published:1998-01 Issue:1-2 Volume:29 Page:161-170
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Fujisawa Shin,Maruta Atsuo,Motomura Shigeki,Fukawa Hitoshi,Kanamori Heiwa,Ogawa Koji,Matsuzaki Michio,Miyashita Hiroko,Harano Hiroshi,Murata Takashi,Sakap Rika,Mohri Hiroshi,Kodama Fumio,Okubo Takao

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428199809058391

Reference21 articles.

1. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B

2. Varying intensity of postremission therapy in acute myeloid leukemia

3. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.

4. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia

5. Randomized study of individualized induction therapy with or without vincristine, and of maintenance—intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 study of the Japan adult leukemia study group

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the Bone Marrow After Therapy;Hematopathology;2011